この記事を読む

オシメルチニブはオリゴPDが多い?

Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study. Schmid S et al. Lung Cancer. …

この記事を読む

臨床研究と観察研究、一致しないのは偶然だけ

Comparison of Population-Based Observational Studies With Randomized Trials in Oncology. Soni PD et al. J Clin Oncol. 20…

この記事を読む

TMBとDNA修復変異との関係

Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Ce…

この記事を読む

PACIFIC試験:欧州でのデュルバルマブの使用制限への反論

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non…

この記事を読む

ICI治療、腺癌での肺臓炎発症は高リスク?

Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy. Sure…

この記事を読む

診断後の禁煙の有用性

Longitudinal study to assess impact of smoking at diagnosis and quitting on 1-year survival for people with non-small ce…

この記事を読む

KEYNOTE-024 最新の生存データ

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cance…

この記事を読む

心身障碍者の肺癌、わずかに高い死亡率だが…

Disparities in the Diagnosis and Treatment of Lung Can∺er among People with Disabilities. Shin DW et al. J Thorac Oncol.…

この記事を読む

再発小細胞肺癌に対するニボルマブの効果

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. Ready N et al. J Thorac Oncol. 2019 Feb;14(2):237-244…

この記事を読む

胸腺腫瘍に対するペムブロリズマブ

Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. Cho J et a…